Arcus Biosciences reports that the combination of Domvanalimab and Zimberelimab enhanced overall survival in the ARC-10 trial involving patients with high PD-L1 NSCLC.

Bepirovirsen, developed by GSK in collaboration with Ionis Pharmaceuticals, is an antisense oligonucleotide that targets the hepatitis B virus (HBV) RNA.

OSE Immunotherapeutics reports noteworthy and statistically significant findings from the Phase 2 trial of Lusvertikimab, an anti-IL7R monoclonal antibody.

Daprodustat is a small molecule drug developed by GSK Plc which primarily targets Hypoxia-Inducible Factor-Prolyl Hydroxylase (HIF-PH) enzymes.

European Medicines Agency Approves Marketing Authorization Application for AVT05, a Biosimilar to Simponi® (golimumab).

Vutrisiran Sodium is a novel RNA interference (RNAi) therapeutic developed by Alnylam Pharmaceuticals.

Korro Bio has announced that it has submitted an application to the Bellberry HREC for a Phase 1/2 clinical trial of KRRO-110 targeting AATD.

AI-driven technological innovation not only enhances the targeting precision of siRNA but also paves new pathways for future gene therapies.

HuidaGene Therapeutics Secures FDA Approval for HG202, the First CRISPR/Cas13 RNA-Editing Treatment for Macular Degeneration.

Cytoki Pharma has dosed the first patient in its Phase 2 trial for CK-0045, targeting obesity and Type 2 diabetes.

Ibrutinib is a medication used primarily in the treatment of certain types of cancer, particularly B-cell malignancies.

Viking Therapeutics has announced that new clinical findings from its VK2735 obesity initiative were featured in two poster sessions at ObesityWeek® 2024.